Physician profile
Sandhya Jyoti Prashad
NPI 1821237991
$157,364.51
in general payments reported to CMS, 2019-2025
21 companies · $2,139 in 2025
The $2,139 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90K · 2020: $9,232 · 2021: $1,906 · 2022: $32K · 2023: $17K · 2024: $4,810 · 2025: $2,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $5,143 · Travel and Lodging: $923 · Education: $22.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,960.00 |
| Food and Beverage | $5,142.90 |
| Travel and Lodging | $923.00 |
| Education | $22.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $148,506.47 | 2019-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $1,227.54 | 2019-2025 | Rexulti, Abilify Maintena |
| Bausch Health US, LLC | $1,196.69 | 2019-2025 | Aplenzin, Wellbutrin |
| Brainsway USA INC | $1,174.19 | 2025 | Deep Tms |
| Lundbeck LLC | $1,129.80 | 2019-2025 | Rexulti |
| Abbvie INC. | $865.29 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $754.34 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $589.32 | 2020-2025 | Caplyta |
| Allergan, INC. | $410.97 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $384.70 | 2019-2023 | Hetlioz |
| Eisai INC. | $279.80 | 2020-2022 | |
| Corium, LLC | $220.19 | 2022-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $217.63 | 2019-2022 | |
| Noven Therapeutics, LLC | $97.90 | 2024-2025 | Xelstrym |
| Axsome Therapeutics, INC. | $70.42 | 2024-2025 | Sunosi, Auvelity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $66.87 | 2020 | |
| Almatica Pharma LLC | $56.56 | 2021 | |
| Janssen Scientific Affairs, LLC | $47.25 | 2019 | |
| Shire North American Group INC | $37.54 | 2019 | |
| Currax Pharmaceuticals LLC | $16.62 | 2022 | |
| Ironshore Pharmaceuticals INC. | $14.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandhya Prashad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.